THE EFFECT OF TOPOISOMERASE ІІ ALPHA ON THE RESPONSE TO NEOADJUVANT CHEMOTHERAPY OF TRIPLE-NEGATIVE BREAST CANCER

Abstract

Summary. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with poor prognosis, lacks of standard biomarkers and tumor heterogeneity. So it is the lack of therapeutic biomarkers and tumor heterogeneity are the main causes of therapeutic resistance in the case of TNBC. Differences in tumor cell properties are provides by enzymes that are important potential therapeutic targets. This is makes the exploring of prognostic biomarkers and potential therapeutic targets of TNBC an important area of research. Aim: to improve treatment outcomes for patients with TNBC by evaluating topoisomerase 2 alpha as a potential predictive marker of treatment efficacy. Objects and methods: the study involved 45 patients with II-III stages of TNBC. In addition to standard biomarkers, the level of topoisomerase II alpha expression was determined by the immunohistochemistry. Instrumental methods of diagnosis, pathomorphological and immunohistochemistry, as well as statistical methods of evaluating the obtained data were used in the study. Results: the taxane-containing chemotherapy regimens in patients with TNBC increases the response to treatment. Topoisomerase II alpha overexpression is associated with better prognosis and response to treatment in patients with TNBC. Conclusions: the main results of study allow us to consider topoisomerase II alpha as a prognostically valuable marker for predicting the course of the disease and the response to chemotherapy, as well as the advantage of taxane-containing treatment regimens in patients with TNBC.